Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have earned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $37.25.

A number of research firms have weighed in on ANRO. HC Wainwright raised their target price on shares of Alto Neuroscience from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. Wedbush increased their price target on Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a report on Thursday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, July 29th. Wolfe Research initiated coverage on Alto Neuroscience in a report on Friday, May 22nd. They issued an “outperform” rating for the company. Finally, BTIG Research raised their target price on Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th.

Institutional Investors Weigh In On Alto Neuroscience

Hedge funds and other institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC purchased a new position in Alto Neuroscience during the first quarter worth about $52,000. Torren Management LLC purchased a new stake in shares of Alto Neuroscience in the 4th quarter valued at approximately $62,000. Invesco Ltd. purchased a new stake in shares of Alto Neuroscience in the 1st quarter valued at approximately $67,000. Bridgeway Capital Management LLC increased its holdings in shares of Alto Neuroscience by 85.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after buying an additional 25,000 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of Alto Neuroscience during the 4th quarter valued at approximately $198,000.

Alto Neuroscience Price Performance

Alto Neuroscience stock opened at $36.17 on Friday. The company has a fifty day simple moving average of $29.70 and a 200-day simple moving average of $24.71. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -14.95 and a beta of 1.13. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. Alto Neuroscience has a 52-week low of $3.41 and a 52-week high of $37.48.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.08. On average, equities analysts anticipate that Alto Neuroscience will post -2.68 EPS for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.